AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31973713 — intervention group
Group type: COMPARATOR
Intervention: Control group (equal caregiver-led contact time with iPad using control apps)
Number of subjects: 46
Study 31287230 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (15 mg once daily)
Number of subjects: 1629
Study 31287230 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (40 mg every other week)
Number of subjects: 1629
Study 31287230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1629
Study 29228946 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention
Number of subjects: 1430
Study 26622083 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed physical activities for 28 weeks
Number of subjects: 100
Study 26622083 — intervention group
Group type: COMPARATOR
Intervention: Control group (no programmed physical activities)
Number of subjects: 100
Study 24840774 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate skin sealant
Number of subjects: 50
Study 24840774 — intervention group
Group type: COMPARATOR
Intervention: Standard measures for preventing contamination
Number of subjects: 50
Study 22814692 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing without dentifrice
Number of subjects: 24
Study 22814692 — intervention group
Group type: COMPARATOR
Intervention: Brushing with dentifrice
Number of subjects: 24
Study 19803612 — intervention group
Group type: EXPERIMENTAL
Intervention: Children and adolescents' perceptions of self-blame and use of secondary control coping (acceptance, distraction, cognitive restructuring, positive thinking)
Number of subjects: 108
Study 19803612 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of current depressive symptoms in parents
Number of subjects: 108
Study 19803612 — intervention group
Group type: EXPERIMENTAL
Intervention: Interparental conflict
Number of subjects: 108
Study 17719366 — intervention group
Group type: EXPERIMENTAL
Intervention: MPC (medical investigations + psychological counselling)
Number of subjects: 127
Study 17719366 — intervention group
Group type: EXPERIMENTAL
Intervention: MC (medical investigations + no psychological counselling)
Number of subjects: 127
Study 17719366 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific postmiscarriage counselling)
Number of subjects: 127
Study 17719366 — intervention group
Group type: EXPERIMENTAL
Intervention: MC and MPC groups (with identified cause of miscarriage)
Number of subjects: 127
Study 15236989 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-activating factor (PAF) treatment during IUI
Number of subjects: 180
Study 11958304 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic group (28 degrees C)
Number of subjects: 30
Study 11958304 — intervention group
Group type: COMPARATOR
Intervention: Tepid group (34 degrees C)
Number of subjects: 30
Study 9717591 — intervention group
Group type: EXPERIMENTAL
Intervention: i.t. sufentanil plus 2.5 mg plain bupivacaine (Group B)
Number of subjects: 50
Study 9717591 — intervention group
Group type: COMPARATOR
Intervention: i.t. sufentanil (Group A)
Number of subjects: 50
Study 10641571 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF injected intradermally into a single dermal metastasis and into a normal skin site for 10 consecutive days at one of four dose levels (10, 20, 40, or 80 microg/injection)
Number of subjects: 16
Study 10641571 — intervention group
Group type: COMPARATOR
Intervention: Uninjected control tumors
Number of subjects: 16
Study 1984617 — intervention group
Group type: EXPERIMENTAL
Intervention: TRACH MATE
Number of subjects: 142
Study 1984617 — intervention group
Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 142
Study 6582073 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin administered 1 hour before a meal
Number of subjects: 20
Study 6582073 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin administered concomitantly with a meal
Number of subjects: 20
Study 6582073 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin administered 1 hour after a meal
Number of subjects: 20
Study 6582073 — intervention group
Group type: COMPARATOR
Intervention: Isotretinoin administered during a complete fast
Number of subjects: 20
Study 6582073 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin administered with food
Number of subjects: 20
Study 30655277 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol 5/5 µg
Number of subjects: 201
Study 30655277 — intervention group
Group type: COMPARATOR
Intervention: tiotropium 5 µg
Number of subjects: 201
Study 30655277 — intervention group
Group type: COMPARATOR
Intervention: tiotropium/olodaterol vs tiotropium
Number of subjects: 201
Study 30046976 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical training intervention for 26 weeks post-RYGB
Number of subjects: 60
Study 30046976 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supervised physical training)
Number of subjects: 60
Study 30046976 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical training intervention
Number of subjects: 60
Study 30046976 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 60
Study 26913372 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 6800
Study 26913372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6800
Study 23210735 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-incisional triamcinolone acetonide (PITMC) injection
Number of subjects: 57
Study 23210735 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intralesional corticosteroids)
Number of subjects: 57
Study 22307136 — intervention group
Group type: EXPERIMENTAL
Intervention: L1CAM downregulation via shRNA
Number of subjects: 0
Study 22307136 — intervention group
Group type: COMPARATOR
Intervention: L1CAM overexpression
Number of subjects: 0
Study 19889502 — intervention group
Group type: EXPERIMENTAL
Intervention: MMD procedural preparation (MMD-PP)
Number of subjects: 80
Study 19889502 — intervention group
Group type: EXPERIMENTAL
Intervention: MMD distraction (MMD-D)
Number of subjects: 80
Study 19889502 — intervention group
Group type: COMPARATOR
Intervention: Standard distraction (SD)
Number of subjects: 80
Study 19889502 — intervention group
Group type: COMPARATOR
Intervention: Hand held video game distraction (VG)
Number of subjects: 80
Study 16876961 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation behaviors
Number of subjects: 0
Study 16876961 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Alternatives
Number of subjects: 0
Study 16876961 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Alternatives, Self-regulation, Assertive Communication
Number of subjects: 0
Study 16336546 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician peer leader intervention
Number of subjects: 40
Study 16336546 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer leaders + asthma education nurses
Number of subjects: 40
Study 16336546 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 16336546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices
Number of subjects: 40
Study 16336546 — intervention group
Group type: EXPERIMENTAL
Intervention: All study arms
Number of subjects: 40
Study 11886474 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg plus amoxicillin 1 g and clarithromycin 500 mg (Group A, n = 46)
Number of subjects: 92
Study 11886474 — intervention group
Group type: COMPARATOR
Intervention: Bismuth subcitrate 125 mg plus tetracycline 500 mg and furazolidone 200 mg (Group B, n = 46)
Number of subjects: 92
Study 11886474 — intervention group
Group type: EXPERIMENTAL
Intervention: No resistance to clarithromycin or amoxicillin
Number of subjects: 92
Study 9032825 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention
Number of subjects: 1689
Study 8344690 — intervention group
Group type: EXPERIMENTAL
Intervention: n-IL-2 therapy
Number of subjects: 10
Study 8344690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3755051 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 8
Study 3755051 — intervention group
Group type: EXPERIMENTAL
Intervention: Brl 20627 (10 mg)
Number of subjects: 8
Study 3755051 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 8
Study 29306931 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus dieting (n=30)
Number of subjects: 50
Study 29306931 — intervention group
Group type: COMPARATOR
Intervention: Dieting (n=20)
Number of subjects: 50
Study 28030544 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap and water
Number of subjects: 91
Study 28030544 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitizer
Number of subjects: 91
Study 28030544 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hypochlorite (HTH)
Number of subjects: 91
Study 28030544 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium dichloroisocyanurate (NaDCC)
Number of subjects: 91
Study 28030544 — intervention group
Group type: EXPERIMENTAL
Intervention: Generated or pH-stabilized sodium hypochlorite (NaOCl)
Number of subjects: 91
Study 28030544 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 91
Study 24885187 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab-containing neoadjuvant therapy
Number of subjects: 27
Study 24885187 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab
Number of subjects: 27
Study 24885187 — intervention group
Group type: EXPERIMENTAL
Intervention: phospho-HER2 measurement
Number of subjects: 27
Study 22325743 — intervention group
Group type: EXPERIMENTAL
Intervention: Communicative pain behaviors (eg, facial expressions)
Number of subjects: 0
Study 22325743 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective pain behaviors (eg, guarding)
Number of subjects: 0
Study 22325743 — intervention group
Group type: COMPARATOR
Intervention: No pain behavior
Number of subjects: 0
Study 20397977 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependent one-lung ventilation (D-OLV)
Number of subjects: 40
Study 20397977 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dependent one-lung ventilation (ND-OLV)
Number of subjects: 40
Study 18776819 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol (oral)
Number of subjects: 36
Study 18776819 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol (oral) + Dexamethasone (intravenous)
Number of subjects: 36
Study 18776819 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (intravenous)
Number of subjects: 36
Study 18776819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15930421 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC (docetaxel plus doxorubicin and cyclophosphamide)
Number of subjects: 1491
Study 15930421 — intervention group
Group type: COMPARATOR
Intervention: FAC (fluorouracil plus doxorubicin and cyclophosphamide)
Number of subjects: 1491
Study 12906021 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Valganciclovir
Number of subjects: 160
Study 12906021 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Ganciclovir
Number of subjects: 160
Study 10589650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (5000 U/kg) administered 2 min before vecuronium (0.1 mg/kg)
Number of subjects: 60
Study 8886680 — intervention group
Group type: EXPERIMENTAL
Intervention: Hartmanns solution
Number of subjects: 0
Study 8886680 — intervention group
Group type: COMPARATOR
Intervention: 5% Dextrose
Number of subjects: 0
Study 1281726 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (10 mg/d)
Number of subjects: 57
Study 1281726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 6374804 — intervention group
Group type: EXPERIMENTAL
Intervention: 750-ml collapsible spacer
Number of subjects: 18
Study 6374804 — intervention group
Group type: COMPARATOR
Intervention: common actuator
Number of subjects: 18
Study 30488466 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasovagal syncope patients
Number of subjects: 76
Study 30488466 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 76
Study 30672174 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture A group (Tongdu Tiaoshen acupuncture, daily treatment)
Number of subjects: 180
Study 30672174 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture B group (Tongdu Tiaoshen acupuncture, treatment every other day)
Number of subjects: 180
Study 30672174 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication group (nimodipine tablets, 30 mg three times daily)
Number of subjects: 180
Study 27554943 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity walking interruptions every 20-min for one day
Number of subjects: 13
Study 27554943 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking interruptions every 20-min for one day
Number of subjects: 13
Study 27554943 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity walking interruptions for three days
Number of subjects: 13
Study 27554943 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted sitting for one day
Number of subjects: 13
Study 27554943 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted sitting for three days
Number of subjects: 13
Study 25029917 — intervention group
Group type: EXPERIMENTAL
Intervention: AP pressure applied to the cervical spine
Number of subjects: 39
Study 25029917 — intervention group
Group type: COMPARATOR
Intervention: Placebo (light touch applied to the right C6 costal process)
Number of subjects: 39
Study 23237076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 80
Study 23237076 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 80
Study 20219059 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (1-desamino-8-D-Arginine Vasopressin) for 7 days
Number of subjects: 20
Study 20219059 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 20
Study 17038158 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking (NW)
Number of subjects: 121
Study 17038158 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking (W)
Number of subjects: 121
Study 16198847 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 522
Study 16198847 — intervention group
Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 522
Study 12393368 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 3 micro g kg(‐1) h(‐1)
Number of subjects: 60
Study 12393368 — intervention group
Group type: COMPARATOR
Intervention: Propofol 1 mg kg(‐1) h(‐1)
Number of subjects: 60
Study 10457148 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral folic acid (5 mg daily for six weeks)
Number of subjects: 18
Study 10457148 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 18
Study 8778134 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-cue anchoring manipulation
Number of subjects: 0
Study 8778134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence anchoring manipulation
Number of subjects: 0
Study 8778134 — intervention group
Group type: EXPERIMENTAL
Intervention: Consider-the-opposite procedure (cue sorting by diagnosticity)
Number of subjects: 0
Study 8778134 — intervention group
Group type: EXPERIMENTAL
Intervention: Note-taking while reviewing cues
Number of subjects: 0
Study 8778134 — intervention group
Group type: EXPERIMENTAL
Intervention: Bias inoculation
Number of subjects: 0
Study 2120769 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg naproxen daily for a week
Number of subjects: 80
Study 2120769 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg naproxen daily for a week
Number of subjects: 80
Study 2120769 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of 750 mg and 1000 mg naproxen
Number of subjects: 80
Study 911007 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily drug reminder chart with concurrent pharmacist supervision
Number of subjects: 0
Study 911007 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29861293 — intervention group
Group type: EXPERIMENTAL
Intervention: LaxVox
Number of subjects: 30
Study 29861293 — intervention group
Group type: EXPERIMENTAL
Intervention: VHFO
Number of subjects: 30
Study 28784312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and fluorouracil (CF); two 3-weekly cycles of cisplatin [80 mg/m2 intravenously on day 1] and fluorouracil [1 g/m2 per day intravenously on days 1-4]
Number of subjects: 897
Study 28784312 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin, cisplatin, and capecitabine (ECX); four 3-weekly cycles of epirubicin [50 mg/m2], cisplatin [60 mg/m2], and capecitabine [1250 mg/m2 daily throughout the four cycles]
Number of subjects: 897
Study 28784312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and fluorouracil (CF)
Number of subjects: 897
Study 28784312 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin, cisplatin, and capecitabine (ECX)
Number of subjects: 897
Study 25815774 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine monotherapy
Number of subjects: 268
Study 23769759 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care intervention (EPC)
Number of subjects: 0
Study 23769759 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study 20705516 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (100 mg) with sulfalene (250 mg) plus pyrimethamine (12.5 mg) for 3 days
Number of subjects: 212
Study 20705516 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel (40 mg/kg per day)
Number of subjects: 212
Study 20705516 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate with sulfalene plus pyrimethamine
Number of subjects: 212
Study 20705516 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel
Number of subjects: 212
Study 18194560 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined biomarker scoring system in the test set
Number of subjects: 313
Study 18194560 — intervention group
Group type: EXPERIMENTAL
Intervention: Test set
Number of subjects: 313
Study 18194560 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation set
Number of subjects: 313
Study 15842977 — intervention group
Group type: EXPERIMENTAL
Intervention: JTT-705 600 mg
Number of subjects: 155
Study 15842977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 12895217 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethylpolysiloxane, sodium bicarbonate and pronase (treatment C)
Number of subjects: 87
Study 12895217 — intervention group
Group type: COMPARATOR
Intervention: Dimethylpolysiloxane alone (treatment A)
Number of subjects: 87
Study 12895217 — intervention group
Group type: COMPARATOR
Intervention: Dimethylpolysiloxane plus sodium bicarbonate (treatment B)
Number of subjects: 87
Study 10526276 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent thoracic irradiation (50 grays in 20 fractions, initiated after the second cycle of chemotherapy)
Number of subjects: 164
Study 10526276 — intervention group
Group type: COMPARATOR
Intervention: Alternating thoracic irradiation (20 grays in 8 fractions followed by 15 grays in 6 fractions, scheduled between chemotherapy cycles)
Number of subjects: 164
Study 8671452 — intervention group
Group type: EXPERIMENTAL
Intervention: Testicular spermatozoa (ICSI)
Number of subjects: 24
Study 8671452 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejaculated spermatozoa (ICSI)
Number of subjects: 24
Study 8671452 — intervention group
Group type: EXPERIMENTAL
Intervention: Total (Testicular + Ejaculated spermatozoa)
Number of subjects: 24
Study 1750634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac
Number of subjects: 60
Study 1750634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6121577 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacetolol 200 mg/day
Number of subjects: 17
Study 6121577 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacetolol 400 mg/day
Number of subjects: 17
Study 6121577 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacetolol 800 mg/day
Number of subjects: 17
Study 30417724 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait (Lokomat, 60% robotic guidance)
Number of subjects: 14
Study 30417724 — intervention group
Group type: COMPARATOR
Intervention: Body weight-supported treadmill walking
Number of subjects: 14
Study 30417724 — intervention group
Group type: COMPARATOR
Intervention: Body weight-supported overground walking
Number of subjects: 14
Study 30417724 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait (Lokomat)
Number of subjects: 14
Study 30417724 — intervention group
Group type: COMPARATOR
Intervention: Body weight-supported treadmill and overground walking
Number of subjects: 14
Study 28129680 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction (MBSR)
Number of subjects: 40
Study 28129680 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 40
Study 25027257 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 149
Study 25027257 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 149
Study 22690324 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy package
Number of subjects: 828
Study 20653165 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Banxia Houpu decoction
Number of subjects: 95
Study 20653165 — intervention group
Group type: COMPARATOR
Intervention: Manyanshuning (Granula for Clearing the Throat)
Number of subjects: 95
Study 19077889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative surfactant treatment (bovine surfactant at a dose of 20 mg phospholipids/kg)
Number of subjects: 42
Study 19077889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative surfactant treatment
Number of subjects: 42
Study 17187138 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ibopamine
Number of subjects: 0
Study 17187138 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% ibopamine
Number of subjects: 0
Study 17187138 — intervention group
Group type: COMPARATOR
Intervention: Control (normal individuals with either 1% or 2% ibopamine)
Number of subjects: 0